Co-Diagnostics Joins Global Health Roundtable Amid Ebola Outbreak Response — Co-Diagnostics, Inc. (Co-Dx)

Event summary

Co-Diagnostics' Chief Commercialization Officer Seth Egan will participate in a Global Health Technologies Coalition (GHTC) and Adjuvant Capital roundtable on September 22, 2026, in New York.
The roundtable will focus on the ongoing Ebola outbreak and technologies needed for effective outbreak response.
Co-Dx's joint venture, CoSara Diagnostics, is advancing Bundibugyo virus and pan-Ebola tests for centralized laboratories.
Co-Dx is collaborating with ReadyGo Diagnostics to evaluate the use of GoCollect® sample-preparation technology with its PCR platform for decentralized Ebola detection.

The big picture

Co-Diagnostics' participation in the GHTC roundtable underscores the growing emphasis on rapid diagnostic solutions for emerging global health threats. The company's focus on Ebola outbreak response aligns with broader industry trends towards decentralized and point-of-care testing technologies. The collaboration with ReadyGo Diagnostics highlights the strategic importance of integrating complementary technologies to enhance outbreak response capabilities.

What we're watching

Regulatory Pathway: Whether Co-Dx's PCR platform can secure necessary regulatory approvals for commercial launch.
Technology Integration: The success of integrating ReadyGo's GoCollect® technology with Co-Dx's PCR platform for streamlined workflow.
Market Expansion: The pace at which Co-Dx can commercialize its diagnostic solutions in strategically important markets.